Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Gains from Investment Securities (2019 - 2023)

China Pharma Holdings (CPHI) has disclosed Gains from Investment Securities for 7 consecutive years, with $207.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Investment Securities changed N/A year-over-year to $207.0, compared with a TTM value of -$203782.0 through Dec 2023, changed N/A, and an annual FY2023 reading of -$45385.0, changed N/A over the prior year.
  • Gains from Investment Securities was $207.0 for Q4 2023 at China Pharma Holdings, up from -$204518.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $236055.0 in Q1 2019 and bottomed at -$204518.0 in Q3 2023.
  • Average Gains from Investment Securities over 3 years is $3232.8, with a median of -$738.0 recorded in 2019.